Search for a trial

A phase 1b, open-label, multi-center, dose-escalation study of the safety, pharmacokinetics and therapeutic activity of cergutuzumab amunaleukin, an immunocytokine, which consists of a variant of interleukin-2 (IL2v) targeting carcinoembryonic antigen (CEA), and atezolizumab, an antibody that targets programmed death ligand 1 (anti-PDL1) administered intravenously, in patients with locally advanced and/or metastatic solid tumors

The primary objectives of this study are:* To describe the safety and tolerability of cergutuzumab amunaleukin in combination with atezolizumab* To determine the MTD, if achieved, of cergutuzumab amunaleukin in combination with atezolizumab* To…